Terns Pharmaceuticals announces data from CARDINAL trial of TERN-701

Terns Pharmaceuticals (TERN) announced that data from the ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor, in participants with previously treated chronic myeloid leukemia, CML, has been selected for oral presentation on December 8, 2025 at the 67th American Society of Hematology, ASH, Annual Meeting and Exposition taking place in Orlando, FL. Highlights include: Of 32 efficacy-evaluable patients: Overall major molecular response rate of 75% by 24 weeks, with 64% achieving MMR and 100% maintaining MMR; Overall MMR by 24 weeks in difficult to treat patient subgroups: 69% in patients with lack of efficacy to last tyrosine kinase inhibitor; 60% in patients who had prior asciminib; 67% in patients with prior asciminib / ponatinib / investigational TKI; No patients had lost MMR at the time of data cutoff. Encouraging safety profile: 87% patients remained on treatment as of the data cut-off; with discontinuations due to disease progression (n=4), adverse events, and consent withdrawal/lost to follow up; No dose-limiting toxicities were observed in dose escalation and a maximum tolerated dose was not reached; The majority of treatment-emergent adverse events were low grade with no apparent dose relationship.